GlaxoSmithKline plc GSK, one of the largest health care companies, reshaped its business following the March 2015 completion of the three-part, inter-conditional transaction with Novartis related to its Consumer Healthcare, Vaccines and Oncology businesses. Under the deal, Glaxo sold its oncology assets to Novartis and acquired Novartis’ Vaccines business (excluding influenza vaccines). Glaxo has created a joint venture (“JV”) with Pfizer earlier in 2019, thereby combining their consumer healthcare unit.
Following the completion of the deal, the UK-based company now focuses on its three core businesses – Pharmaceuticals (respiratory, HIV), Vaccines (pediatric, adolescent, adult, and travel vaccines) and Consumer Healthcare (wellness, oral health, nutrition and skin health products). However, Glaxo is currently focusing on its core assets and divesting non-core assets.
Meanwhile, like many of its peers, Glaxo is facing challenges in the form of stiff competition, genericization and pricing pressure. In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential, restructuring and cost-cutting initiatives and performance of new products apart from the usual top-and bottom-line numbers.
Glaxo’s performance has been decent so far, with the company’s earnings beating expectations in three of the trailing four quarters, while missing the same once. Overall, the company has delivered an average positive surprise of 12.54%.
Currently, Glaxo has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: Glaxo reported core earnings of 93 cents per American depositary share in the first quarter of 2020, which beat our consensus estimate of 79 cents. Core earnings surged 26% year over year at constant exchange rate (“CER”).
Revenues Beat: Revenues were up 19% year over year at CER to $11.26 billion (£9.1 billion). Revenues also beat the Zacks Consensus Estimate of $10.95 billion.
Key Stats: Sales in Vaccines segment surged 19% at CER while Consumer Healthcare sales increased 46%. Growth in Consumer Healthcare segment was heavily driven by consumer and government responses to the COVID-19 pandemic. Pharmaceuticals sales were also up 6% at CER. The Respiratory segment increased 38% at CER. HIV product sales were up 8% at CER.
2020 Guidance: Based on its current assessment of COVID-19 impact, Glaxo maintained its previous guidance for adjusted EPS to decline 1% to 4% at CER, year over year, in 2020. However, it will be updated later, if needed.
Share Price Impact: Shares were up 0.2% in pre-market trading.
Check back later for our full write up on GSK earnings report later!
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Access Zacks Top 10 Stocks for 2020 today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
GlaxoSmithKline plc (GSK) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research